A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Atopic Dermatitis

In brief

The main purpose of this study is to describe the efficacy and safety of LY3454738 in adult participants with moderate-to-severe atopic dermatitis (AD).

Key facts

Study ID

NCT05911841

Run by

Eli Lilly and Company

People needed

234

Starts

2023-06-21

Expected to finish

2025-03-14

Last updated by the study team

2025-12-02

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Are candidates for systemic therapy.
• ISA specific:
• Have moderate-to-severe AD, defined as meeting all of the following criteria, at the first dosing visit:
• EASI score greater than or equal to (≥)16
• vIGA-AD score ≥3, and
• ≥10% of BSA involvement (per EASI BSA).
• Have applied at least 1 emollient every day for at least 2 weeks before the day of the first dose of study intervention in this ISA and agree to daily use of at least 1 emollient continuously throughout the study.

You may not qualify if…

• ISA specific:
• Have, in the screening period, any of the skin conditions, infections, or medical conditions listed under master IMMB.
• Are currently being treated with topical or systemic therapy
• Recent treatment with experimental (biologics and/or small molecules) - doesn't apply for subset of participants who must have been exposed to biologics and/or small molecules.

Where it is running

• Arkansas Research Trials — North Little Rock, Arkansas, United States
• Dermatology Research Associates — Los Angeles, California, United States
• Encore Medical Research — Hollywood, Florida, United States
• Conquest Research — Winter Park, Florida, United States
• Allergy and Asthma Specialist — Owensboro, Kentucky, United States
• Revival Research Institute, LLC — Troy, Michigan, United States
• ActivMed Practices & Research, Inc. — Portsmouth, New Hampshire, United States
• Metropolitan Dermatology - Clark — Kenilworth, New Jersey, United States
• Oregon Dermatology and Research Center — Portland, Oregon, United States
• DermDox Centers for Dermatology — Camp Hill, Pennsylvania, United States
• Progressive Clinical Research — San Antonio, Texas, United States
• Center for Clinical Studies — Webster, Texas, United States
• Rejuvenation Dermatology — Calgary, Alberta, Canada
• Rejuvenation Dermatology — Edmonton, Alberta, Canada
• Wiseman Dermatology Research Inc. — Winnipeg, Manitoba, Canada
• CCA Medical Research — Ajax, Ontario, Canada
• Hamilton Allergy — Hamilton, Ontario, Canada
• Lynderm Research Inc. — Markham, Ontario, Canada
• FACET Dermatology — Toronto, Ontario, Canada
• Alpha Recherche Clinique — Québec, Canada
• Xiangya Hospital Central South University — Changsha, Hunan, China
• Affiliated Hospital of Jiangsu University — Zhenjiang, Jiangsu, China
• The First Affiliated Hospital of Xi'an Jiaotong University — Xi'an, Shaanxi, China
• Huashan Hospital, Fudan University — Shanghai, Shanghai Municipality, China
• Johnson Dermatology — Fort Smith, Arkansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.